Physician profile
Jade Hensinger
NPI 1215536008
$7,979.56
in general payments reported to CMS, 2019-2025
48 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,270 · 2022: $3,659 · 2023: $2,564 · 2024: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,727 · Education: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,726.65 |
| Education | $324.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $940.05 | 2021-2023 | Tysabri, Vumerity, Avonex |
| Alexion Pharmaceuticals, INC. | $848.41 | 2021-2024 | Ultomiris, Soliris |
| Abbvie INC. | $656.65 | 2021-2024 | |
| Ucb, INC. | $596.14 | 2022-2023 | Briviact, Cimzia |
| Lilly USA, LLC | $436.64 | 2021-2024 | Reyvow, Emgality, Kisunla |
| Teva Pharmaceuticals USA, INC. | $435.47 | 2021-2023 | Austedo, Austedo Xr |
| Amgen INC. | $289.01 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $284.78 | 2021-2023 | Rytary |
| Biohaven Pharmaceutical Holding Company Ltd. | $253.71 | 2022 | |
| Argenx US, INC. | $228.62 | 2022-2023 | Vyvgart Hytrulo, Vyvgart |
| Genzyme Corporation | $212.96 | 2021-2023 | |
| Ani Pharmaceuticals, INC. | $211.09 | 2022-2023 | Purified Cortrophin Gel |
| Lundbeck LLC | $176.40 | 2021-2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $174.25 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $164.65 | 2021-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jade Hensinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.